Anti-IgE therapy with omalizumab reduces serum levels of free IgE and downregulates
expression of IgE receptors (FcεRI) on mast cells and basophils. In the airways of patients
with mild allergic asthma, omalizumab reduces FcεRI+ and IgE+ cells and causes a
profound reduction in tissue eosinophilia, together with reductions in submucosal T-cell and
B-cell numbers. In patients with seasonal allergic rhinitis, omalizumab inhibits the allergen-
induced seasonal increases in circulating and tissue eosinophils. Omalizumab decreases …